MEDICAL POLICY

POLICY TITLE	**MOLECULAR ANALYSIS (INCLUDING LIQUID BIOPSY) FOR TARGETED THERAPY OR IMMUNOTHERAPY OF NON-SMALL CELL LUNG CANCER**
POLICY NUMBER	**MP 2.241**

CLINICAL BENEFIT	☒ MINIMIZE SAFETY RISK OR CONCERN. ☒ MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. ☐ ASSURE APPROPRIATE LEVEL OF CARE. ☐ ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. ☒ ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. ☐ ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
Effective Date:	**2/1/2025**

I. POLICY

In the absence of FDA-labeled contraindications to requested therapies, molecular analyses will be approved as follows:

EGFR Testing

Analysis of somatic variants in exons 18 through 21 (e.g., G719X, L858R, T790M, S6781, L861Q) within the epidermal growth factor receptor (*EGFR*), may be considered **medically necessary** to predict treatment response to an FDA- approved therapy in individuals with advanced and metastatic non-small cell lung cancer (NSCLC).

Analysis of tumor tissue for somatic variants in exon 20 (e.g., insertion mutations) within the *EGFR* gene, may be considered **medically necessary** to predict treatment response to an FDA-approved therapy in individuals with NSCLC.

Analysis of other *EGFR* variants within exons 22 to 24, or other applications related to NSCLC is considered **investigational**. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with these procedures.

EGFR Testing – Liquid biopsy/Plasma

At diagnosis: only analysis of somatic variants in exons 19 through 21 (e.g., exon 19 deletions, L858R, T790M) within the *EGFR* gene, using plasma specimens to detect circulating tumor (ctDNA) with one of the following:

- the cobas EGFR Mutation Test v2,
- Guardant360 CDx test,
- FoundationOne Liquid CDx
- OncoBEAM test, or
- InVisionFirst-Lung test

may be considered **medically necessary** as an alternative to tissue biopsy (see Policy Guidelines) to predict treatment response to an EGFR tyrosine kinase inhibitor therapy in individuals with advanced or metastatic NSCLC.

Analysis using Agilent Resolution ctDx FIRST or LiquidHALLMARK is considered **investigational**, as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

At progression: analysis of the EGFR T790M resistance variant for targeted therapy with osimertinib using plasma specimens to detect ctDNA with one the following:

- the cobas EGFR Mutation Test v2,
- Guardant360 CDx test,
- OncoBEAM test, or
- InVisionFirst-Lung test

may be considered **medically necessary** in patients with advanced or metastatic NSCLC when tissue biopsy to obtain new tissue is not feasible.

Analysis of plasma for somatic variants in exon 20 (e.g., insertion mutations) within the *EGFR* gene using an FDA-approved companion diagnostic plasma test to detect ctDNA may be considered **medically necessary**.

Plasma Testing When Tissue is Insufficient

Plasma tests for oncogenic driver variants deemed medically necessary on tissue biopsy may be considered **medically necessary** to predict treatment response to targeted therapy for patients meeting the following criteria:

- Patient does not have sufficient tissue for standard molecular testing using formalin-fixed paraffin-embedded tissue; **OR**
- The patient is considered medically unfit for invasive tissue sampling **AND**
- An FDA-approved test is available.

* Follow-up tissue-based analysis is recommended should no driver variant be identified via plasma testing

Analysis of Somatic Rearrangement Variants

Analysis of somatic rearrangement variants using tumor tissue, or plasma testing when tissue is insufficient (as above), to predict treatment response is **medically necessary** in individuals with advanced or metastatic non-small cell lung cancer as follows:

- ALK Testing
- ROS1 Testing
- KRAS Testing
- HER2 Testing
- MET Exon 14 Skipping Alteration Testing

Analysis of somatic rearrangement variants using tumor tissue to predict treatment response is **medically necessary** in individuals with advanced or metastatic non-small cell lung cancer as follows:

- BRAF V600E Testing
- RET Rearrangement Testing

Analysis of somatic rearrangement variants of the above listed genes is considered **investigational** in all other situations. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with these procedures.

Analysis using Protean BioDiagnostics LungHDPCR testing is considered investigational, as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

NTRK Gene Fusion Testing
Analysis of somatic NTRK gene fusions may be considered **medically necessary** to predict treatment response in patients with advanced and metastatic NSCLC.

Analysis of somatic NTRK gene fusions is considered **investigational** in all other situations. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with these procedures.

PD-L1 Testing
PD-L1 testing may be considered **medically necessary** to predict treatment response in patients with advanced and metastatic NSCLC.

PD-L1 testing is considered **investigational** in all other situations. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with these procedures.

Tumor Mutational Burden
Analysis of tumor mutational burden for targeted therapy in patients with NSCLC is considered **investigational**. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with these procedures.

*If coverage of a test is requested, but is not listed above, please refer to **MP 2.259 - Expanded Molecular Panel Testing of Cancers to Identify Targeted Therapies for additional guidance**.*

Policy Guidelines
These gene tests, including the ctDNA tests, are intended for use in patients with advanced (stage III or IV) non-small-cell lung cancer.

Guidelines from the National Comprehensive Cancer Network on non-small-cell lung cancer provide recommendations for biomarker testing. Guidelines are updated frequently; refer to the source document for current recommendations. The most recent guidelines recommend that EGFR variants and ALK rearrangement testing and PD-L1 testing (category 1) as well as KRAS, ROS1, BRAF and NTRK1/2/3, MET Exon 14 skipping alteration, RET testing, and HER2 testing (category 2A) be performed in the workup of non-small-cell lung cancer in patients with metastatic disease with histologic subtypes adenocarcinoma, large cell

carcinoma, and non-small-cell lung cancer not otherwise specified. The guidelines add that testing should be conducted as part of broad molecular profiling, defined as a single assay or a combination of a limited number of assays and that it is acceptable to have a tiered approach based on low-prevalence, co-occurring biomarkers. The guidelines additionally recommend identifying the emerging biomarker, high-level MET amplification, while noting that the definition of this biomarker is evolving and may differ according to the assay used.

The 2018 guidelines issued jointly by the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology have recommended the following:

> "One set of genes must be offered by all laboratories that test lung cancers, as an absolute minimum: EGFR, ALK, and ROS1. A second group of genes should be included in any expanded panel that is offered for lung cancer patients: BRAF, MET, RET, ERBB2 (HER2), and KRAS, if adequate material is available. KRAS testing may also be offered as a single-gene test to exclude patients from expanded panel testing. All other genes are considered investigational at the time of publication."

Histologic Subtype for Non-Small Cell Lung Cancer (NSCLC) per the NCCN

Histologic Subtype for NSCLC
Adenocarcinoma
Large cell carcinoma
NSCLC not other specified
Squamous cell carcinoma

https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

II. PRODUCT VARIATIONS

TOP

This policy is only applicable to certain programs and products administered by Capital Blue Cross please see additional information below, and subject to benefit variations as discussed in Section VI below.

FEP PPO - Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at:

https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies .

III. DESCRIPTION/BACKGROUND

TOP

NON-SMALL-CELL LUNG CANCER

Treatment options for non-small-cell lung cancer (NSCLC) depend on disease stage and include various combinations of surgery, radiotherapy, systemic therapy, and best supportive care. Unfortunately, in up to 85% of cases, the cancer has spread locally beyond the lungs at diagnosis, precluding surgical eradication. Also, up to 40% of patients with NSCLC present with metastatic disease. When treated with standard platinum-based chemotherapy, patients with

advanced NSCLC have a median survival of 8 to 11 months and a 1-year survival of 30% to 45%. The identification of specific, targetable oncogenic "driver mutations" in a subset of NSCLCs has resulted in a reclassification of lung tumors to include molecular subtypes, which are predominantly of adenocarcinoma histology. Testing for epidermal growth factor receptor (*EGFR*) variants and anaplastic lymphoma kinase (*ALK*) rearrangements is routine in clinical decision making for the treatment of NSCLC. The use of testing for other variants to direct targeted therapy continues to evolve.

EGFR Gene

EGFR, a receptor tyrosine kinase (TK), is frequently overexpressed and activated in NSCLC. Drugs that inhibit EGFR signaling either prevent ligand binding to the extracellular domain (monoclonal antibodies) or inhibit intracellular TK activity (small-molecule tyrosine kinase inhibitors [TKIs]). These targeted therapies dampen signal transduction through pathways downstream to the EGFR, such as the RAS/RAF/MAPK cascade. RAS proteins are G proteins that cycle between active and inactive forms in response to stimulation from cell surface receptors, such as EGFR, acting as binary switches between cell surface EGFR and downstream signaling pathways. These pathways are important in cancer cell proliferation, invasion, metastasis, and stimulation of neovascularization.

Variants in 2 regions of the *EGFR* gene (exons 18-24)—small deletions in exon 19 and a point variant in exon 21 (L858R)—appear to predict tumor response to TKIs such as erlotinib. Likewise, tumors with an acquired exon 20 (T790M) substitution variant appear to respond to osimertinib following the failure of TKI therapy.

The prevalence of *EGFR* variants in NSCLC varies by population, with the highest prevalence in nonsmoking Asian women with adenocarcinoma, in whom *EGFR* variants have been reported to be up to 30% to 50%. The reported prevalence in the white population is approximately 10%.

ALK Gene

ALK is a TK that, in NSCLC, is aberrantly activated because of a chromosomal rearrangement that leads to a fusion gene and expression of a protein with constitutive TK activity that has been demonstrated to play a role in controlling cell proliferation. The *EML4-ALK* fusion gene results from an inversion within the short arm of chromosome 2.

The *EML4-ALK* rearrangement ("*ALK*-positive") is detected in 3% to 6% of NSCLC patients, with the highest prevalence in never-smokers or light ex-smokers who have adenocarcinoma.

BRAF Gene

RAF proteins are serine/threonine kinases that are downstream of RAS in the RAS-RAF-ERK-MAPK pathway. In this pathway, the *BRAF* gene is the most frequently mutated in NSCLC, in 1% to 3% of adenocarcinomas. Unlike melanoma, about 50% of the variants in NSCLC are non-V600E variants. Most *BRAF* variants occur more frequently in smokers.

ROS1 Gene
ROS1 codes for a receptor TK of the insulin receptor family, and chromosomal rearrangements result in fusion genes. The prevalence of *ROS1* fusions in NSCLC varies from 0.9% to 3.7%. Patients with *ROS1* fusions are typically never-smokers with adenocarcinoma.

KRAS Gene
The *KRAS* gene (which encodes RAS proteins) can harbor oncogenic variants that result in a constitutively activated protein, independent of signaling from the EGFR, possibly rendering a tumor resistant to therapies that target the EGFR. Variants in the *KRAS* gene, mainly codons 12 and 13, have been reported in 20% to 30% of NSCLC, and occur most often in adenocarcinomas in heavy smokers. KRAS variants can be detected by direct sequencing, PCR technologies, or NGS. *EGFR*, *ALK*, *ROS1*, and *KRAS* driver mutations are considered to be mutually exclusive.

HER2 Gene
Human epidermal growth factor receptor 2 (*HER2*) is a member of the HER (EGFR) family of TK receptors and has no specific ligand. When activated, it forms dimers with other EGFR family members. *HER2* is expressed in approximately 25% of NSCLC. *HER2* variants are detected mainly in exon 20 in 1% to 2% of NSCLC, predominantly in adenocarcinomas in nonsmoking women.

RET Gene
RET (rearranged during transfection) is a proto-oncogene that encodes a receptor TK growth factor. Translocations that result in fusion genes with several partners have been reported. *RET* fusions occur in 0.6% to 2% of NSCLCs and 1.2% to 2% of adenocarcinomas.

MET Gene
MET amplification is one of the critical events for acquired resistance in *EGFR*-mutated adenocarcinomas refractory to EGFR TKIs.

NTRK Gene Fusions
NTRK gene fusions encode tropomyosin receptor kinase fusion proteins that act as oncogenic drivers for solid tumors including lung, salivary gland, thyroid, and sarcoma. It is estimated that NTRK gene fusions occur in 0.2% of patients with NSCLC and do not typically overlap with other oncogenic drivers.

PD-1/PD-L1
Programmed cell ligand-1 (PD-L1) is a transmembrane protein expressed on the surface of multiple tissue types, including many tumor cells. Blocking the PD-L1 protein may prevent cancer cells from inactivating T cells.

Tumor Mutational Burden
Tumor mutational burden, a measure of gene mutations within cancer cells, is an emerging biomarker of outcomes with immunotherapy in multiple tumor types, including lung cancer.

Targeted Treatment, Immunotherapy, and Companion Diagnostic Testing
Targeted treatments, immunotherapy, and FDA-approved companion diagnostic tests are available on the FDA site https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools

IV. RATIONALE

TOP

Summary of Evidence
For individuals who have advanced-stage NSCLC who are being considered for targeted therapy who receive testing for *EGFR* variants and *ALK* rearrangements, the evidence includes phase 3 studies comparing tyrosine kinase inhibitors (TKIs) (e.g., afatinib, erlotinib, gefitinib, osimertinib, et al) with chemotherapy. Relevant outcomes are overall survival (OS), disease-specific survival, test validity, quality of life (QOL), and treatment-related morbidity. Studies have shown that TKIs are superior to chemotherapy regarding tumor response rate and progression-free survival (PFS), with a reduction in toxicity and improvement in QOL. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have advanced-stage NSCLC who are being considered for targeted therapy who receive testing for *BRAF* variants and *ROS1* rearrangements, the evidence includes nonrandomized trials and observational studies of BRAF and MEK inhibitors and crizotinib or ceritinib, respectively. Relevant outcomes are OS, disease-specific survival, test validity, QOL, and treatment-related morbidity. Studies have shown that combination therapy with dabrafenib and trametinib for *BRAF* V600E- variant NSCLC and crizotinib for NSCLC with *ROS1* rearrangements result in response rates of 60% and 70%, respectively, with acceptable toxicity profiles. In an analysis of 53 patients with *ROS-1* fusion-positive NSCLC enrolled in 3 ongoing clinical trials of entrectinib, the objective response rate was 77%, with a median duration of response of 24.6 months and acceptable toxicity. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have advanced-stage NSCLC who are being considered for targeted therapy who receive testing for *RET* or *MET* gene testing, the evidence includes nonrandomized trials of kinase inhibitors. Relevant outcomes are OS, disease-specific survival, test validity, QOL, and treatment-related morbidity. Studies have shown efficacy in PFS and duration of response for selpercatinib and pralsetinib in patients with RET-fusion positive NSCLC, and for capmatinib in patients with *MET* Exon 14 skipping alterations, with acceptable toxicity. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have advanced-stage NSCLC who are being considered for targeted therapy who receive testing for KRAS as a technique to predict treatment nonresponse to anti-EGFR therapy with TKIs or testing for HER2 variants to select the use of the anti-EGFR monoclonal antibody cetuximab (Erbitux), the evidence includes post hoc analysis of trials, observational studies, and meta-analyses. Relevant outcomes are OS, disease-specific survival, test validity, QOL, and treatment-related morbidity. Data on the role of *KRAS* variants in NSCLC and response to erlotinib are available from post hoc analysis of trials, observational

studies, and meta-analyses. Although studies have shown that *KRAS* variants in patients with NSCLC confer a high level of resistance to TKIs, data are insufficient to assess any additional benefit to *KRAS* testing beyond *EGFR* testing. In 2 randomized trials with post hoc analyses of *KRAS* variant status and use of the anti-EGFR monoclonal antibody cetuximab with chemotherapy, *KRAS* variants did not identify patients who would benefit from anti-EGFR antibodies, because outcomes with cetuximab were similar regardless of *KRAS* variant status, Studies for *HER2* variant testing have reported response rates and PFS in numbers of patients too small from which to draw conclusions. The evidence is insufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have advanced-stage NSCLC who receive testing for KRAS to select targeted treatment, the evidence includes a phase 2, open-label trial of sotorasib in patients with KRAS variant NSCLC. Relevant outcomes are OS, disease-specific survival, test validity, QOL, and treatment-related morbidity. Presence of the KRAS alteration in tissue was confirmed on central laboratory testing with the use of the therascreen KRAS RGQ PCR Kit. Among 124 patients evaluated for the primary outcome, 4 (3.2%) had a complete response and 42 (33.9%) had a partial response, with an acceptable safety profile. Median duration of response was 11.1 months (95% confidence interval [CI]: 6.9 to not evaluable). The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have advanced-stage NSCLC who are being considered for targeted therapy who receive NTRK gene fusion testing, the evidence includes nonrandomized trials of larotrectinib and entrectinib in patients with solid tumors. Relevant outcomes are OS, disease-specific survival, test validity, QOL, and treatment-related morbidity. In 55 patients with consecutively and prospectively identified tropomyosin receptor kinase fusion-positive solid tumors who received larotrectinib, including 4 patients with lung tumors, the overall response rate was 80% (95% CI, 67 to 90). The median PFS had not been reached after a median follow-up duration of 9.9 months (range, 0.7 to 25.9). Responses were observed regardless of tumor type or age of the patient. In an integrated analysis of 3 phase 1-2 trials in patients with NTRK solid tumors who received entrectinib, 10 of whom had NSCLC, response was 57% (95% CI 43.2% to 70.8%) with an acceptable safety profile. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have advanced-stage NSCLC who are being considered for immunotherapy with fam-trastuzumab deruxtecan-nxki who receive somatic testing for *HER2* variants, the evidence includes a multicenter, blinded, and randomized dose-optimization trial. Relevant outcomes are OS, disease-specific survival, test validity, QOL, and treatment-related morbidity. In the DESTINY-Lung02 trial, patients with activating *HER2* mutations who have received prior systemic therapy demonstrated an objective response rate (ORR) of 58% (95% CI, 43% to 71%) and median duration of response of 8.7 months (95% CI, 7.1 months to not estimable) when treated with the novel antibody-drug conjugate trastuzumab deruxtecan. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have advanced-stage NSCLC who are being considered for immunotherapy who receive PD-L1 testing, the evidence includes RCTs comparing immunotherapy to chemotherapy. Relevant outcomes are OS, disease-specific survival, test validity, QOL, and

treatment-related morbidity. In RCTs, patients with high PD-L1 expression had longer PFS and fewer adverse events when treated with anti-PD-L1 monoclonal antibodies than with platinum chemotherapy. In the KEYNOTE trial, first-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome. For individuals who have advanced-stage NSCLC who are being considered for immunotherapy who receive tumor mutational burden (TMB) testing, the evidence includes a RCT and retrospective observational studies. In a subgroup analysis of the KEYNOTE trial, PFS was significantly longer with nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high TMB ($\geq$10 mutations per megabase). In exploratory analyses, retrospective observational studies have reported an association between higher TMB and longer PFS and OS in patients receiving immunotherapy. These results need to be confirmed in additional, well-designed prospective studies. Additionally, there is no consensus on how to measure TMB. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have advanced-stage NSCLC who receive testing for biomarkers of EGFR TKIs sensitivity using ctDNA with the cobas EGFR Mutation Test v2, Guardant360 CDx, FoundationOne Liquid CDx, OncoBEAM, or InVision tests (liquid biopsy), the evidence includes numerous studies assessing the diagnostic characteristics of liquid biopsy compared with tissue. Relevant outcomes are OS, disease-specific survival, and test validity. Current evidence does not permit determining whether cobas or tissue biopsy is more strongly associated with patient outcomes or treatment response. BCBSA identified no RCTs providing evidence of the clinical utility of cobas. The cobas EGFR Mutation Test has adequate evidence of clinical validity for the EGFR TKI-sensitizing variants. The cobas, Guardant360 CDx, and FoundationOne Liquid CDx tests have received FDA-approval as companion diagnostics for EGFR-sensitizing variants and are therefore not subject to extensive evidence review. The OncoBEAM and InVision tests have adequate evidence of clinical validity for the EGFR TKI-sensitizing variants. The U.S. Food and Drug Administration has suggested that a strategy of liquid biopsy followed by referral (reflex) tissue biopsy of negative liquid biopsies for the cobas test would result in an overall diagnostic performance equivalent to tissue biopsy. Several additional studies of the clinical validity of cobas have shown it to be moderately sensitive and highly specific compared with a reference standard of tissue biopsy. A chain of evidence demonstrates that the reflex testing strategy with the cobas test should produce outcomes similar to tissue testing while avoiding tissue testing in approximately two-thirds of patients with EGFR TKI-sensitizing variants. Patients who cannot undergo tissue biopsy would likely otherwise receive chemotherapy. The cobas test can identify patients for whom there is a net benefit of targeted therapy versus chemotherapy with high specificity. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have advanced-stage NSCLC who progressed on *EGFR* TKIs who receive testing for biomarkers of *EGFR* TKI resistance using ctDNA (liquid biopsy) with tests other than the cobas EGFR Mutation Test v2, Guardant360 CDx, OncoBEAM, or InVision tests, the evidence includes studies assessing the diagnostic characteristics of liquid biopsy. Relevant outcomes are OS, disease-specific survival, and test validity. Given the breadth of molecular

diagnostic methodologies available to assess ctDNA, the clinical validity of each commercially available test must be established independently. None of the other commercially available tests have multiple studies of adequate quality to estimate the performance characteristics for detection of the *EGFR* T790M variant with sufficient precision. Current evidence does not permit determining whether a liquid biopsy or tissue biopsy is more strongly associated with patient outcomes or treatment response. BCBSA found no RCTs providing evidence of the clinical utility of these methods of liquid biopsy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have advanced-stage NSCLC who receive testing for biomarkers of EGFR TKI sensitivity using ctDNA with tests other than the cobas EGFR Mutation Test v2, Guardant360 CDx, OncoBEAM, or InVision tests, the evidence includes studies assessing the diagnostic characteristics of liquid biopsy compared with tissue reference standard. Relevant outcomes are OS, disease-specific survival, and test validity. Given the breadth of molecular diagnostic methodologies available to assess ctDNA, the clinical validity of each commercially available test must be established independently. None of the commercially available tests other than the cobas, Guardant360 CDx, OncoBEAM, and InVision tests have multiple studies of adequate quality to estimate the performance characteristics with sufficient precision. Current evidence does not permit determining whether a liquid biopsy or tissue biopsy is more strongly associated with patient outcomes or treatment response. BCBSA found no RCTs providing evidence of the clinical utility of these methods of liquid biopsy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with advanced-stage NSCLC who are being considered for targeted therapy who undergo testing for ALK rearrangements using FoundationOne Liquid CDx, the evidence includes an exploratory retrospective analysis of data from a RCT comparing crizotinib to alectinib, and 1 clinical bridging study that compared FoundationOne Liquid to another liquid biopsy test. Relevant outcomes are OS, disease-specific survival, and test validity. There are no studies directly comparing FoundationOne liquid to tissue biopsy. Clinical validity has not been demonstrated in multiple well-designed and conducted studies; therefore, a chain of indirect evidence to show clinical utility cannot be established. One nonrandomized trial directly assessed the clinical utility of FoundationOne Liquid to select patients for treatment with alectinib, but this study was limited by its lack of a control group and no comparison to tissue biopsy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with advanced-stage NSCLC who are being considered for targeted therapy who undergo testing for MET exon 14 skipping alterations using FoundationOne Liquid CDx, the evidence includes a clinical bridging study that compared FoundationOne Liquid to tissue testing using data from a nonrandomized, open-label phase 2 study of capmatinib therapy. Relevant outcomes are OS, disease-specific survival, and test validity. There is no direct evidence of the clinical utility of FoundationOne Liquid to select patients for targeted therapy for capmatinib. Clinical validity has not been demonstrated in multiple well-designed and conducted studies, and therefore a chain of indirect evidence to show clinical utility cannot be established. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have advanced-stage NSCLC who receive testing for biomarkers other than EGFR using a liquid biopsy to select a targeted therapy, the evidence includes studies assessing the diagnostic characteristics of liquid biopsy compared with the tissue biopsy reference standard. Relevant outcomes are OS, disease-specific survival, and test validity. Given the breadth of molecular diagnostic methodologies available to assess ctDNA, the clinical validity of each commercially available test must be established independently. None of the commercially available tests have multiple studies of adequate quality to estimate the performance characteristics with sufficient precision for variants other than EGFR. BCBSA found no RCTs providing evidence of the clinical utility of those methods of liquid biopsy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have advanced-stage NSCLC who progressed on EGFR TKIs who receive testing for biomarkers of EGFR TKI resistance using liquid biopsy, the evidence includes studies assessing the diagnostic characteristics of liquid biopsy. Relevant outcomes are OS, disease-specific survival, and test validity. For variants that indicate EGFR TKI resistance and suitability for alternative treatments with osimertinib, liquid biopsy is moderately sensitive and moderately specific compared with a reference standard of tissue biopsy. Given the moderate clinical sensitivity and specificity of liquid biopsy, using liquid biopsy alone or in combination with tissue biopsy might result in the selection of different patients testing positive for EGFR TKI resistance. It cannot be determined whether patient outcomes are improved. However, although there is higher discordance in the liquid versus tissue results for the resistance variant, retrospective analyses have suggested that patients positive for T790M in liquid biopsy have outcomes with osimertinib that appear to be similar overall to patients positive by a tissue-based assay. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. Although the evidence is limited, the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology published joint guidelines endorsed by American Society of Clinical Oncology with an expert consensus opinion that physicians may use liquid biopsy (cell-free DNA) to identify EGFR T790M variants in patients with progression or resistance to EGFR-targeted TKIs and that testing of the tumor sample is recommended if the liquid biopsy result is negative. Similarly, the National Comprehensive Cancer Network guidelines also state that at progression on erlotinib, afatinib, gefitinib or dacomitinib when testing for the T790M resistance variant, liquid biopsy should be considered and when a liquid biopsy is negative tissue-based testing is strongly recommended.

V. DEFINITIONS

TOP

NA

VI. BENEFIT VARIATIONS

TOP

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations should be based in all cases on the applicable health benefit plan language. Medical policies do not constitute a description of

benefits. A member's health benefit plan governs which services are covered, which are excluded, which are subject to benefit limits, and which require preauthorization. There are different benefit plan designs in each product administered by Capital Blue Cross. Members and providers should consult the member's health benefit plan for information or contact Capital Blue Cross for benefit information.

VII. DISCLAIMER

TOP

Capital Blue Cross' medical policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member's plan of benefits, please contact Capital Blue Cross' Provider Services or Member Services. Capital Blue Cross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

TOP

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Investigational; therefore, not covered when used to test for genetic alterations in the geneTMB for targeted therapy in patients with NSCLC:

Procedures codes								
81404	81405	81479	0478U					

Investigational; therefore, not covered for cell-free DNA testing

Procedure Codes								
0179U	0409U	0436U	81479	0485U				

Covered when medically necessary (tissue testing):

Procedure Codes								
81191	81192	81193	81194	81210	81235	81275	81276	81401
81404	81405	81445	81450	81455	81457	81458	81459	81479

POLICY TITLE	MOLECULAR ANALYSIS (INCLUDING LIQUID BIOPSY) FOR TARGETED THERAPY OR IMMUNOTHERAPY OF NON-SMALL CELL LUNG CANCER
POLICY NUMBER	MP 2.241

Procedure Codes								
88342	88363	88365	0022U	0037U	0334U	0473U		

Covered when medically necessary for plasma/cell-free DNA testing with cobas EGFR Mutation testv2, Guardant 360 test, OncoBEAM test, FoundationOne Liquid CDx, or InVisionFirst-Lung test OR for plasma testing when tissue is insufficient:

Procedure Codes								
0239U	0242U	0326U	81235	81277	81445	81450	81455	81462
81463	81464	81479	86152	86153				

ICD-10-CM Diagnosis Codes	Description
C34.00	Malignant neoplasm of unspecified main bronchus
C34.01	Malignant neoplasm of right main bronchus
C34.02	Malignant neoplasm of left main bronchus
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung
D38.1	Neoplasm of uncertain behavior of trachea, bronchus and lung

IX. REFERENCES

TOP

1. *Fathi AT, Brahmer JR. Chemotherapy for advanced stage non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2008; 20(3): 210-6. PMID 19038730*

2. *Martoni A, Marino A, Sperandi F, et al. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer. Jan 2005; 41(1): 81-92. PMID 15617993*
3. *Rudd RM, Gower NH, Spiro SG, et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol. Jan 01 2005; 23(1): 142-53. PMID 15625369*
4. *Thunnissen E, van der Oord K, den Bakker M. Prognostic and predictive biomarkers in lung cancer. A review. Virchows Arch. Mar 2014; 464(3): 347-58. PMID 24420742*
5. *National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 7.2024. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.*
6. *Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. May 31 2018; 378(22): 2093-2104. PMID 29658845*
7. *Food and Drug Administration. List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools).*
8. *Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs.*
9. *Fang W, Zhang J, Liang W, et al. Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation. J Thorac Dis. Oct 2013; 5(5): 585-92. PMID 24255770*
10. *Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol. Jun 2006; 11(3): 190-8. PMID 16850125*
11. *Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. Sep 01 2005; 23(25): 5900-9. PMID 16043828*
12. *Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. Sep 03 2009; 361(10): 958-67. PMID 19692684*
13. *Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. Apr 15 2013; 19(8): 2240-7. PMID 23470965*
14. *Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. Mar 23 2011; 3(75): 75ra26. PMID 21430269*
15. *Mujoomdar M, Moulton K, Spry C. Epidermal Growth Factor Receptor Mutation Analysis in Advanced Non-Small Cell Lung Cancer: A Review of the Clinical Effectiveness and Guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2010.*
16. *Food and Drug Administration (FDA). Summary of Safety and Effectiveness Data (SSED): therascreen EGFR RGQ PCR Kit. 2013*
17. *Food and Drug Administration (FDA). Summary of Safety and Effectiveness Data (SSED): cobas EGFR Mutation Test. 2013*

18. *Food and Drug Administration (FDA). Summary of Safety and Effectiveness Data (SSED): cobas EGFR Mutation Test v2. 2015*
19. *Food and Drug Administration (FDA). Summary of Safety and Effectiveness Data (SSED): OncomineTM Dx Target Test. 2017*
20. *Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. Nov 2013; 31(11): 1023-31. PMID 24142049*
21. *Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. May 01 2013; 105(9): 595-605. PMID 23594426*
22. *Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Epidermal growth factor receptor (EGFR) mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer. TEC Assessments. 2007;Volume 22:Tab 6.*
23. *Guetz GD, Landre T, Uzzan B, et al. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis. Target Oncol. Feb 2016; 11(1): 41-7. PMID 26092590*
24. *Kato T, De Marinis F, Spicer J, et al. The impact of first-line tyrosine kinase inhibitors (TKIs) on overall survival in patients with advanced non-small cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations: meta-analysis of major randomized trials by mutation type. Value Health. Nov 2015;18(7):A436. PMID 26532455*
25. *Kuan FC, Kuo LT, Chen MC, et al. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. Br J Cancer. Nov 17 2015; 113(10): 1519-28. PMID 26461059*
26. *Greenhalgh J, Dwan K, Boland A, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. May 25 2016; (5): CD010383. PMID 27223332*
27. *Petrelli F, Borgonovo K, Cabiddu M, et al. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer. Mar 2012; 13(2): 107-14. PMID 22056888*
28. *Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. Sep 2015; 26(9): 1883-1889. PMID 26105600*
29. *Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. Mar 2012; 13(3): 239-46. PMID 22285168*
30. *Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. Aug 2011; 12(8): 735-42. PMID 21783417*
31. *Zhou C, Wu YL, Chen G, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive*

advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. Sep 2015; 26(9): 1877-1883. PMID 26141208

32. *Ahn MJ, Park BB, Ahn JS, et al. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?. Clin Cancer Res. Jun 15 2008; 14(12): 3860-6. PMID 18559606*
33. *Amann JM, Lee JW, Roder H, et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol. Feb 2010; 5(2): 169-78. PMID 20035238*
34. *Felip E, Rojo F, Reck M, et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res. Jun 15 2008; 14(12): 3867-74. PMID 18559607*
35. *Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. Mar 20 2008; 26(9): 1472-8. PMID 18349398*
36. *Schneider CP, Heigener D, Schott-von-Romer K, et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. J Thorac Oncol. Dec 2008; 3(12): 1446-53. PMID 19057271*
37. *Giaccone G, Gallegos Ruiz M, Le Chevalier T, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res. Oct 15 2006; 12(20 Pt 1): 6049-55. PMID 17062680*
38. *Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. Mar 01 2007; 25(7): 760-6. PMID 17228019*
39. *Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. Sep 10 2008; 26(26): 4268-75. PMID 18626007*
40. *Yoshioka H, Hotta K, Kiura K, et al. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J Thorac Oncol. Jan 2010; 5(1): 99-104. PMID 19898258*
41. *Sim EH, Yang IA, Wood-Baker R, et al. Gefitinib for advanced non-small cell lung cancer. Cochrane Database Syst Rev. Jan 16 2018; 1: CD006847. PMID 29336009*
42. *Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. Sep 03 2009; 361(10): 947-57. PMID 19692680*
43. *Han B, Jin B, Chu T, et al. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial. Int J Cancer. Sep 15 2017; 141(6): 1249-1256. PMID 28560853*
44. *Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. Feb 2010; 11(2): 121-8. PMID 20022809*

45. *Wu YL, Saijo N, Thongprasert S, et al. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Lung Cancer. Feb 2017; 104: 119-125. PMID 28212993*
46. *Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. Jun 24 2010; 362(25): 2380-8. PMID 20573926*
47. *Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. Jan 2013; 24(1): 54-9. PMID 22967997*
48. *Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. Sep 20 2013; 31(27): 3327-34. PMID 23816960*
49. *Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. Sep 20 2013; 31(27): 3342-50. PMID 23816967*
50. *Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. Feb 2014; 15(2): 213-22. PMID 24439929*
51. *Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. May 2012; 13(5): 539-48. PMID 22452895*
52. *Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. May 2012; 13(5): 528-38. PMID 22452896*
53. *Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. Sep 20 2013; 31(27): 3335-41. PMID 23816963*
54. *Food and Drug Administration (FDA). TAGRISSOTM (osimertinib) Highlights of Prescribing Information. 2015*
55. *Yang J, Ramalingam SS, Janne PA, et al. LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M- positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. J Thorac Oncol. Apr 2016;11(4 Suppl):S152-153. PMID 27198353*
56. *Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. Aug 28 2018: JCO2018783118. PMID 30153097*
57. *Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. Feb 16 2017; 376(7): 629-640. PMID 27959700*

58. *Lin JZ, Ma SK, Wu SX, et al. A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?. Medicine (Baltimore). Jul 2018; 97(30): e11569. PMID 30045282*
59. *Zhang W, Wei Y, Yu D, et al. Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis. Medicine (Baltimore). Apr 2018; 97(16): e0460. PMID 29668619*
60. *De Mello RA, Escriu C, Castelo-Branco P, et al. Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis. Oncotarget. Feb 20 2018; 9(14): 11805-11815. PMID 29545937*
61. *Crequit P, Chaimani A, Yavchitz A, et al. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis. BMC Med. Oct 30 2017; 15(1): 193. PMID 29082855*
62. *Wu D, Duan C, Wu F, et al. Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy. Oncotarget. Sep 12 2017; 8(39): 66491-66503. PMID 29029530*
63. *Yang Z, Hackshaw A, Feng Q, et al. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis. Int J Cancer. Jun 15 2017; 140(12): 2805-2819. PMID 28295308*
64. *Zhang Y, Zhang Z, Huang X, et al. Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials. Clin Lung Cancer. Sep 2017; 18(5): e333-e340. PMID 28462807*
65. *Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. Jan 11 2018; 378(2): 113-125. PMID 29151359*
66. *Urata Y, Katakami N, Morita S, et al. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. J Clin Oncol. Sep 20 2016; 34(27): 3248-57. PMID 27022112*
67. *Yang JJ, Zhou Q, Yan HH, et al. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer. Feb 28 2017; 116(5): 568-574. PMID 28103612*
68. *Park K, Tan EH, O'Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. May 2016; 17(5): 577-89. PMID 27083334*
69. *Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res. Apr 15 2011; 17(8): 2081-6. PMID 21288922*
70. *Food and Drug Administration (FDA). FDA approves crizotinib capsules. 2016*
71. *Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. Dec 04 2014; 371(23): 2167-77. PMID 25470694*
72. *Food and Drug Administration (FDA). Summary of Safety and Effectiveness Data (SSED): Ventana ALK (D5F3) CDx Assay. 2015*
73. *Shaw AT, Kim TM, Crino L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib*

(ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. Jul 2017; 18(7): 874-886. PMID 28602779

74. *Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. Mar 04 2017; 389(10072): 917-929. PMID 28126333*
75. *Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. Jul 01 2017; 390(10089): 29-39. PMID 28501140*
76. *Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. Feb 2016; 17(2): 234-242. PMID 26708155*
77. *Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. Aug 31 2017; 377(9): 829-838. PMID 28586279*
78. *Gadgeel S, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. Nov 01 2018; 29(11): 2214-2222. PMID 30215676*
79. *Camidge DR, Kim DW, Tiseo M, et al. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. J Clin Oncol. Sep 10 2018; 36(26): 2693-2701. PMID 29768119*
80. *Ventana. VENTANA ALK (D5F3) CDx Assay - P140025. 2015*
81. *Planchard D, Kim TM, Mazieres J, et al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol. May 2016; 17(5): 642-50. PMID 27080216*
82. *Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. Jul 2016; 17(7): 984-993. PMID 27283860*
83. *Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. Oct 2017; 18(10): 1307-1316. PMID 28919011*
84. *Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. Aug 20 2015; 373(8): 726-36. PMID 26287849*
85. *Gautschi O, Pauli C, Strobel K, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol. Oct 2012; 7(10): e23-4. PMID 22743296*
86. *Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. Nov 20 2014; 371(21): 1963-71. PMID 25264305*
87. *Lim SM, Kim HR, Lee JS, et al. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. J Clin Oncol. Aug 10 2017; 35(23): 2613-2618. PMID 28520527*
88. *Mazieres J, Zalcman G, Crino L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. Mar 20 2015; 33(9): 992-9. PMID 25667280*

89. *Kim HR, Lim SM, Kim HJ, et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol. Sep 2013; 24(9): 2364-70. PMID 23788756*
90. *Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. Aug 27 2020; 383(9): 813-824. PMID 32846060*
91. *Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. Jun 24 2021; 384(25): 2371-2381. PMID 34096690*
92. *Pan W, Yang Y, Zhu H, et al. KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies. Oncotarget. Feb 16 2016; 7(7): 8373-88. PMID 26840022*
93. *Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer. Sep 2010; 69(3): 272-8. PMID 20022659*
94. *Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. Oct 2008; 9(10): 962-72. PMID 18804418*
95. *Papadimitrakopoulou V, Lee JJ, Wistuba II, et al. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. Oct 20 2016; 34(30): 3638-3647. PMID 27480147*
96. *Rulli E, Marabese M, Torri V, et al. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. Ann Oncol. Oct 2015; 26(10): 2079-84. PMID 26209642*
97. *Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. Jul 14 2005; 353(2): 123-32. PMID 16014882*
98. *Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. Jan 2005; 2(1): e17. PMID 15696205*
99. *Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. Sep 01 2005; 23(25): 5892-9. PMID 16043829*
100. *Fiala O, Pesek M, Finek J, et al. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy. Anticancer Res. Apr 2013; 33(4): 1705-11. PMID 23564819*
101. *Guan JL, Zhong WZ, An SJ, et al. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy. Ann Surg Oncol. Apr 2013; 20(4): 1381-8. PMID 23208128*
102. *Boldrini L, Ali G, Gisfredi S, et al. Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study. Oncol Rep. Oct 2009; 22(4): 683-91. PMID 19724844*
103. *Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. Feb 20 2010; 28(6): 911-7. PMID 20100966*
104. *Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line*

taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. Feb 20 2010; 28(6): 918-27. PMID 20100958

105.Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. May 02 2009; 373(9674): 1525-31. PMID 19410716

106.O'Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol. Aug 2011; 12(8): 795-805. PMID 21782507

107.Janne PA, van den Heuvel MM, Barlesi F, et al. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. JAMA. May 09 2017; 317(18): 1844-1853. PMID 28492898

108.Blumenschein GR, Smit EF, Planchard D, et al. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). Ann Oncol. May 2015; 26(5): 894-901. PMID 25722381

109.Mok T, Ladrera G, Srimuninnimit V, et al. Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer. Lung Cancer. Aug 2016; 98: 1-8. PMID 27393499

110.Shen H, Du G, Liu Z, et al. Assessment and prognostic analysis of EGFR mutations or/and HER2 overexpression in Uygur's Non-small Cell Lung Cancer. Int J Clin Exp Med. 2015; 8(12): 22300-9. PMID 26885207

111.Mazieres J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. Jun 01 2013; 31(16): 1997-2003. PMID 23610105

112.Food and Drug Administration Center for Drug Evaluation and Research. Multi-Discipline Review of Pralsetinib (2020).

113.Wolf J, Seto T, Han JY, et al. Capmatinib in MET Exon 14-Mutated or MET -Amplified Non-Small-Cell Lung Cancer. N Engl J Med. Sep 03 2020; 383(10): 944-957. PMID 32877583

114.Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. Feb 22 2018; 378(8): 731-739. PMID 29466156

115.Food and Drug Administration (FDA). NDA Multidisciplinary Review and Evaluation NDA 210861 and NDA 211710 VITRAKVI (larotrectinib), 2018.

116.Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. Apr 2020; 21(4): 531-540. PMID 32105622

117.Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. Feb 2020; 21(2): 271-282. PMID 31838007

118.Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. Oct 01 2020; 383(14): 1328-1339. PMID 32997907

119.Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. Nov 10 2016; 375(19): 1823-1833. PMID 27718847

120.Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. Nov 21 2019; 381(21): 2020-2031. PMID 31562796

121.Rizvi H, Sanchez-Vega F, La K, et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J Clin Oncol. Mar 01 2018; 36(7): 633-641. PMID 29337640

122.Singal G, Miller PG, Agarwala V, et al. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. JAMA. Apr 09 2019; 321(14): 1391-1399. PMID 30964529

123.Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. Oct 2020; 21(10): 1353-1365. PMID 32919526

124.Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. Aug 04 2011; 365(5): 395-409. PMID 21714641

125.Lee JK, Hahn S, Kim DW, et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA. Apr 09 2014; 311(14): 1430-7. PMID 24715074

126.Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. Apr 30 2015; 372(18): 1689-99. PMID 25923549

127.Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. Jun 14 2018; 378(24): 2288-2301. PMID 29863955

128.Wu Y, Liu H, Shi X, et al. Can EGFR mutations in plasma or serum be predictive markers of non-small-cell lung cancer? A meta-analysis. Lung Cancer. Jun 2015; 88(3): 246-53. PMID 25837799

129.Supplee JG, Milan MSD, Lim LP, et al. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA. Lung Cancer. Aug 2019; 134: 96-99. PMID 31320002

130.Papadimitrakopoulou VA, Han JY, Ahn MJ, et al. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Cancer. Jan 15 2020; 126(2): 373-380. PMID 31769875

131.Jenkins S, Yang JC, Ramalingam SS, et al. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. Jul 2017; 12(7): 1061-1070. PMID 28428148

132.Food and Drug Administration (FDA). cobas EGFR Mutation Test v2 (P150047). 2016;

133. Karlovich C, Goldman JW, Sun JM, et al. Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). Clin Cancer Res. May 15 2016; 22(10): 2386-95. PMID 26747242
134. Thress KS, Brant R, Carr TH, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. Dec 2015; 90(3): 509-15. PMID 26494259
135. Mok T, Wu YL, Lee JS, et al. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clin Cancer Res. Jul 15 2015; 21(14): 3196-203. PMID 25829397
136. Weber B, Meldgaard P, Hager H, et al. Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer. Apr 28 2014; 14: 294. PMID 24773774
137. Palmero R, Taus A, Viteri S, et al. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced NonSmall-Cell Lung Cancer. JCO Precis Oncol. 2021;(5):93-102.
138. Food and Drug Administration. Guardant360 CDx. 2020;
139. Leighl NB, Page RD, Raymond VM, et al. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res. Aug 01 2019; 25(15): 4691-4700. PMID 30988079
140. Schwaederle MC, Patel SP, Husain H, et al. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clin Cancer Res. Sep 01 2017; 23(17): 5101-5111. PMID 28539465
141. Thompson JC, Yee SS, Troxel AB, et al. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. Clin Cancer Res. Dec 01 2016; 22(23): 5772-5782. PMID 27601595
142. Villaflor V, Won B, Nagy R, et al. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget. Oct 11 2016; 7(41): 66880-66891. PMID 27602770
143. Ramalingam SS, Yang JC, Lee CK, et al. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. Mar 20 2018; 36(9): 841-849. PMID 28841389
144. Mellert H, Foreman T, Jackson L, et al. Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non-Small Cell Lung Carcinoma. J Mol Diagn. May 2017; 19(3): 404-416. PMID 28433077
145. Paweletz CP, Sacher AG, Raymond CK, et al. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. Clin Cancer Res. Feb 15 2016; 22(4): 915-22. PMID 26459174
146. Pritchett MA, Camidge DR, Patel M, et al. Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With

Advanced Nonsquamous NonSmall-Cell Lung Cancer. JCO Precision Oncology 2019 :3, 1-15.

147. *Remon J, Lacroix L, Jovelet C, et al. Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced NonSmall-Cell Lung Cancer. JCO Precision Oncology 2019 :3, 1-14*
148. *Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED) FoundationOne Liquid CDx. 2020*
149. *Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED) Guardant360 CDx. 2020*
150. *Sacher AG, Paweletz C, Dahlberg SE, et al. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol. Aug 01 2016; 2(8): 1014-22. PMID 27055085*
151. *Guo QM, Wang L, Yu WJ, et al. Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay. J Cancer. 2019; 10(18): 4341-4349. PMID 31413754*
152. *Zhang Y, Xu Y, Zhong W, et al. Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR. Oncotarget. Jan 24 2017; 8(4): 5861-5873. PMID 28052016*
153. *Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED) cobas EGFR Mutation Test v2. 2016*
154. *Karachaliou N, Mayo-de las Casas C, Queralt C, et al. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. JAMA Oncol. May 2015; 1(2): 149-57. PMID 26181014*
155. *Oxnard GR, Thress KS, Alden RS, et al. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. Oct 01 2016; 34(28): 3375-82. PMID 27354477*
156. *Helman E, Nguyen M, Karlovich CA, et al. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor. Clin Lung Cancer. Nov 2018; 19(6): 518-530.e7. PMID 30279111*
157. *Chen Y, Han T, Zhou Y, et al. Comparing the efficacy of targeted next-generation sequencing in the identification of somatic mutations in circulating tumor DNA from different stages of lung cancer. Neoplasma. Jul 23 2019; 66(4): 652-660. PMID 31058536*
158. *Tran VT, Phan TT, Nguyen ST, et al. Smoking habit and chemo-radiotherapy and/or surgery affect the sensitivity of EGFR plasma test in non-small cell lung cancer. BMC Res Notes. Aug 03 2020; 13(1): 367. PMID 32746896*
159. *Merker JD, Oxnard GR, Compton C, et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. Jun 01 2018; 36(16): 1631-1641. PMID 29504847*
160. *Food and Drug Administration. Summary of Safety and Effectiveness Data. FoundationOne Liquid CDx. 2020.*
161. *Dziadziuszko R, Mok T, Peters S, et al. Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. J Thorac Oncol. Jul 24 2021. PMID 34311110*

162.Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. May 2013; 143(5 Suppl): e341S-e368S. PMID 23649446

163.Hanna NH, Robinson AG, Temin S, et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol. Mar 20 2021; 39(9): 1040-1091. PMID 33591844

164.Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. Jun 2013; 137(6): 828-60. PMID 23551194

165.Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. Mar 2018; 20(2): 129-159. PMID 29398453

166.Protean BioDiagnostics, LungHDPCR, www.proteanbiodx.com/lung-hdpcr

167.National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Version 7.2024.

168.Rolfo C, Mack P, Scagliotti GV, et al. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021;16(10):1647-1662. doi:10.1016/j.jtho.2021.06.017

169.Aggarwal C, Marmarelis ME, Hwang WT, et al. Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023;7:e2300191. doi:10.1200/PO.23.00191

170.Centers for Medicare and Medicaid Services. Next Generation Sequencing. 2020.

171.Blue Cross Blue Shield Association Medical Policy Reference Manual. 2.04.45, Molecular Analysis (including Liquid Biopsy) for Targeted Therapy of Non-Small-Cell Lung Cancer. December 2023.

X. POLICY HISTORY

Top

MP 2.241	**09/10/2020 Consensus Review.** No changes made to the policy statement. Policy guidelines, product variation, description, rationale, benefit variation, disclaimer, and references updated. Coding reviewed.
	09/22/2020 Administrative Update. New codes 81191, 81192, 81193, 81194 added. Effective 1/1/2021.
	05/24/2021 Minor Review. RET and MET testing are MN and KRAS and HER2 remain INV. Added PD-L1 criteria. Updated tables, background, references and rationale. Coding updated for criteria changes.
	02/02/2022 Major Review. MP 2.283 was retired (Circulating Tumor DNA management of NSCLC) and merged with this policy. Criteria from MP

	2.283 (related to ctDNA) was copied and revised as follows: EGFR testing (at diagnosis) was changed from: exons 18 through 21 to: exons 19 through 21; acomitinib was added to list of EGFR TKIs; HER2, RET rearrangement testing, and MET exon 14 skipping remain INV, denial statement expanded from one collective to three separate. KRAS testing (in tissue) was revised from INV to medically necessary. Analysis of tumor mutational burden statement revised; INV status unchanged. Plasma testing when tissue is insufficient was added as MN with criteria. Literature, references and coding updated.
	06/10/2022 Administrative Update. Added new code 0326U as MN effective 7/1/22
	09/12/2022 Administrative Update. Added code 0334U effective 10/1/22
	07/31/2023 Minor Review. Added MN statement regarding testing for Exon 20. Added FoundationOne as MN for liquid biopsy testing. Added Agilent ResolutionFirst and LiquidHALLMARK as INV. Added MN statement for liquid biopsy testing for ALK, ROS1, KRAS, HER2, and MET; condensed for readability. Reformatted sections on plasma testing for readability. Added statement to reference MP 2.259. Removed tables from background. Updated policy guidelines, background, rationale, references. Place 0326U in coding table.
	12/12/2023 Administrative Update. Added code 0436U as INV. Added codes 81457, 81458, 81459, 81462, 81463, and 81464 as MN. Eff 1/1/2024.
	06/12/2024 Administrative Update. Added code 0473U as MN. Eff 7/1/2024.
	09/30/2024 Administrative Update. New codes 0478U and 0485U added effective 10/1/2024
	10/28/2024 Minor Review. Added Lung HDPCR as INV with code 0478U eff 10/1/24. Added code 0409U as INV. Updated references.
	12/27/2024 Administrative Update. Removed NCCN statement.

Top